Date: 2015-10-31
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Genzyme (USA - MA), a Sanofi company (France)
Product: GZ402668
Action
mechanism: monoclonal antibody. GZ402668 is a next-generation investigational anti-CD52 humanized monoclonal antibody.
Disease: progressive multiple sclerosis
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Country: Germany
Trial
details: This randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending single intravenous and subcutaneous doses of GZ402668 in men and women with progressive multiple sclerosis. (NCT02282826)
Latest news:
